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Apoptosis plays a fundamental part in epidermal
homeostasis, and apoptotic cells have been detected
in normal and diseased skin. Little is known, however,
on the inhibitory mechanisms of apoptosis at the skin
level. In addition to bcl-2, a novel inhibitor of apoptosis
designated survivin and structurally analogous to IAP
apoptosis inhibitors has been recently identified. The
expression of survivin in normal and pathologic skin
was investigated. Immunohistochemical studies
revealed that survivin is expressed in basal keratino-
cytes, but not in suprabasal epidermal layers, with a
pattern similar to bcl-2. In western blots, the anti-
survivin antibody recognized a single band of 16.5 kDa
in protein extracts from normal human keratinocytes
in culture, in agreement with the predicted size of
Apoptosis, or programmed cell death, is a physiologicprocess of gene-directed cell suicide (Raff, 1992).Derangements of apoptosis may trigger several diseasestates, such as viral infection, neurodegenerative dis-orders and cancer (Thompson, 1995). In the skin,
apoptosis plays an important part in morphogenesis (LeBrun et al,
1993; Polakowska et al, 1994) and homeostasis (Budtz, 1994;
Polakowska and Haake, 1994). It has been shown recently that
keratinocytes possess reversible physiologic defenses against
spontaneous and ultraviolet light-induced apoptosis (Norris et al,
1997; Pincelli et al, 1997). Similarly, human melanocytes are
protected from ultraviolet-induced apoptosis by neurotrophic
proteins (Zhai et al, 1996 ) secreted in a paracrine fashion by other
skin cells (Yaar et al, 1994). On the other hand, loss of normal
apoptosis may be involved in the development of skin cancer.
Indeed, in ultraviolet-induced skin cancer, inactivation of the tumor
suppressor gene p53 reduces the appearance of ‘‘sunburn cells’’,
apoptotic keratinocytes that might have incurred mutations and
thus are to be eliminated (Ziegler et al, 1994). Bcl-2 is a major
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survivin. In addition, survivin immunoreactivity was
detected in benign and malignant melanocytic lesions,
with strong expression in invasive lesions of
melanomas. Whereas survivin staining was undetect-
able in benign epithelial tumors, such as seborrheic
keratoses, it was observed in all epidermal layers in
Bowen’s disease. Interestingly, at variance with bcl-2,
survivin was markedly expressed in squamous cell
carcinoma, but virtually lacking in basal cell car-
cinoma, suggesting that these two apoptosis inhibitors
may act through different anti-apoptotic pathways.
Deregulation of survivin may influence both epidermal
homeostasis and the development of melanoma and
nonmelanoma skin cancer. Key words: epidermis/IAP
proteins/skin cancer. J Invest Dermatol 113:415–418, 1999
anti-apoptotic protein (Kroemer, 1997) that is expressed in normal
keratinocytes and melanocytes (Rodriguez-Villanueva et al, 1995).
Aberrant expression of bcl-2 has been involved in tumor develop-
ment (Fanidi et al, 1992), and changes in bcl-2 levels have
been observed in melanoma (Kanter-Lewenshon et al, 1997) and
nonmelanoma (Cerroni and Kerl, 1994; Morales-Ducret et al, 1995)
skin cancers.
Recently, a family of anti-apoptotic cellular genes related to the
baculovirus iap gene has been described (Duckett et al, 1996; Uren
et al, 1996). The iap genes display two distinct structural features,
a carboxyl-terminal RING finger and an amino-terminal repeat
termed baculovirus IAP repeat (BIR) (Lovering et al, 1993; Clem
and Miller, 1994). IAP proteins inhibit apoptosis in different
contexts (Liston et al, 1996), although their mechanism of action
is not completely understood. Recent studies show that human
X-chromosome-linked IAP directly inhibit two members of the
caspase family of cell death proteases (Deveraux et al, 1997). Survivin
is a novel gene encoding a structurally unique IAP apoptosis
inhibitor, containing a single BIR domain, but lacking the RING
finger. Survivin inhibits apoptosis induced by interleukin-3 with-
drawal in B cell precursors (Ambrosini et al, 1997). Moreover, it
has been shown recently that survivin is expressed in HeLa cells in
a cell-cycle regulated manner and associates with microtubules
during mitosis. Disruption of survivin–microtubule interaction
results in loss of survivin’s anti-apoptotic function (Li et al, 1998).
Survivin has been detected in several human cancers, such as lung,
breast, colon, and pancreas adenocarcinoma and in non-Hodgkin
lymphoma, whereas it has not been found in most normal adult
tissues (Ambrosini et al, 1997, 1998). Because little is known on
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Fig 1. Expression of survivin in normal adult skin.
Tissue sample was formalin-fixed, paraffin embedded,
and stained with anti-survivin antibody. Scale bar: 100 µm
(a). Protein extracts from cultured normal human
keratinocytes were separated on 12% polyacrylamide gels
and transferred onto nitrocellulose membrane.
Membranes were immunoblotted with anti-survivin
antibody (lane 2) or nonimmune rabbit IgG (lane 3).
Jurkat cell line was used as a positive control (lane 1) (b).
the inhibitory mechanisms of apoptosis and in particular on IAP
proteins at the skin level, we investigated the expression of survivin
in normal skin. In addition, we studied the expression of this
protein in benign and malignant skin tumors, to evaluate the
possible role of survivin in skin cancer.
MATERIALS AND METHODS
Tissue procurement A total of 56 cases of human skin retrieved from
the archives of the Anatomic Pathology was used in this study. The
distribution was as follows: two normal adult skin and one fetal skin, three
solar keratoses, two seborrheic keratoses, one keratoacanthoma, eight basal
cell carcinomas (BCC, seven nodulocystic and one superficial), four
Bowen’s diseases, seven squamous cell carcinomas (SCC), two junctional
nevi, two dermal nevi, one compound nevus, three Spitz nevi, six in situ
melanomas, five infiltrating melanomas (four in vertical phase, one in radial
growth pattern), two cutaneous metastases of melanoma, one Merkel cell
tumor, two low-grade B cell lymphomas, two T cell lymphoma, one
pseudolymphoma, and one Jessner–Kanof infiltrate.
Immunohistochemistry Five micron sections cut from formalin-fixed,
paraffin-embedded specimens were deparaffinized in xylene and
rehydrated in graded alcohol. Quenching of the endogenous peroxidase
activity was obtained by treatment with 6% H2O2 in methanol. The slides
were first boiled in pH 6 citrate buffer for 15 min in a standard
pressure cooker, then incubated with undiluted supernatant of anti-
survivin monoclonal antibody (kindly supplied by Professor Dario Altieri,
Department of Pathology, Yale University) at 4°C overnight. After three
washes of 5 min in phosphate-buffered saline (PBS), slides were incubated
with biotin-conjugated anti-mouse antibody (Linker reagent, Bioptica,
Italy) for 30 min at room temperature, followed by incubation with
conjugated streptavidin–horseradish peroxidase for 30 min (Tracer reagent,
Bioptica, Italy). After three washes of 5 min in PBS, the slides were stained
with 39,39-diaminobenzidine for 10 min, then counterstained for 5 min
with hematoxylin. In control experiments, endogenous biotin was blocked
by applying avidin for 30 min, followed by biotin for 30 min (Endogenous
Biotin Blocking Kit, Ventana, CA) prior to the application of the
biotinylated detection reagent. Negative controls, obtained by substituting
supernatant with normal serum, and positive controls (colonic adeno-
carcinoma) were also included in the study. A further control was performed
by preabsorption of the antiserum with recombinant survivin (1.7 mg
per ml).
Western blot analysis Normal human keratinocytes and Jurkat cells
were washed with PBS and lysed on ice in RIPA buffer pH 8.5 (50 mM
Tris–HCl, 150 mM NaCl, 1% deoxycolate, 1% TritonX-100, 0.1% SDS,
0.2% sodium azide) containing phenylmethylsulfonyl fluoride (4 mM,
Sigma, St Louis, MO), aprotinin (0.2 trypsin inhibitory unit per ml, Sigma),
and leupeptin (10 mg per ml, Sigma). After boiling in Laemmli sample
buffer, 50 mg of total protein were analyzed under reducing conditions
on 12% polyacrylamide gels and transferred on to nitrocellulose membrane.
To verify equal loading of total protein in all lanes, the membrane was
stained with red ponceau. The blot was blocked for 2 h in blocking buffer
(PBS buffer, pH 7.4 with 0.2% Tween 20 and 5% nonfat milk) and
incubated with anti-survivin or rabbit IgG antibody overnight at 4°C. Then
membranes were washed in PBS/Tween 20, incubated with peroxidase-
conjugated goat anti-rabbit antibody (1:800) for 45 min at room temper-
ature, washed and developed using the ECL chemiluminescent detection
system (Amersham, Milano, Italy).
RESULTS
Expression of survivin in normal adult skin Survivin
immunoreactivity (S-IR) was observed as a cytoplasmic staining in
the epidermal basal layer of normal human skin, the intensity
Table I. Survivin expression in pathologic skin
No. (positive/total) Staining intensity
Pigmented lesions
melanocytic nevi 4/5 12/1
Spitz nevi 3/3 1/11 (focal)
in situ MM 6/6 1/11 (focal)
invasive MM 5/5 1/11
metastatic MM 2/2 1/11
Epithelial lesions
solar keratoses 0/3 2
seborrheic keratoses 0/2 2
Bowen’s disease 3/4 1 (all layers)
keratoacanthoma 1/1 12 (only basal cells)
SCC 6/7 1/11 (focal)
BCC 1/8 12
Others
B cell lymphomas 1/2 2/12
T cell lymphomas 0/2 2
pseudolymphomas 1/1 2/12
Merkel cell carcinoma 1/1 12/1
2, no S-IR; 12, weak S-IR; 1, moderate S-IR; 11, strong S-IR; MM,
malignant melanoma.
ranging from faint to (focally) moderate. No S-IR was detected in
the suprabasal layers (Fig 1a). Epithelial cells of the adnexa
(sebaceous and sweat glands, follicular outer root sheath) were also
stained. In particular, at variance with bcl-2, no difference was
observed in staining intensity between the different epithelial
components of eccrine sweat glands (Rodriguez-Villanueva et al,
1995). Whereas follicular epithelium express high levels of bcl-2
in anagen, catagen phase of the cell cycle is associated with apoptosis
and characterized by decreased bcl-2 protein (Stenn et al, 1994).
In this study, survivin was expressed mostly in the follicular outer
root sheath. More detailed studies, however, are required to evaluate
the potential role of survivin in hair cycling. Fetal skin showed
very faint staining in the epidermal basal layer, in agreement with
previous observation (Adida et al, 1998)
To confirm that survivin is expressed in the basal layer of
normal adult human epidermis, keratinocytes derived from newborn
foreskin were cultured in serum-free defined medium which selects
mostly basal cells. In western blots performed on proteins extracted
from these cells the anti-survivin antibody recognized a single band
of 16.5 kDa (Fig 1b). A band of the same molecular weight
corresponding to survivin was also observed in Jurkat cell lines,
used as a positive control (Ambrosini et al, 1997). In contrast, no
specific bands were immunoblotted by the addition of rabbit IgG
under the same experimental conditions.
Expression of survivin in pathologic skin (Table I) S-IR
was observed in four of five benign melanocytic lesions, both in
the junctional and in the dermal component (Fig 2a). A strong
survivin expression was also detected in all Spitz nevi (Fig 2b).
Among malignant neoplasms, all melanomas expressed moderate-
to-marked S-IR. Immunostaining was stronger in invasive lesions
(Fig 2c) and metastatic deposits than in in situ melanomas. No
difference in staining intensity was observed between melanomas
in radial and in vertical growth phase.
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Fig. 2. Expression of survivin in pathologic
skin. Intradermal naevus (a), Spitz naevus (b),
invasive melanoma (c), SCC (d), Bowen’s disease
(e). Scale bars: (a, c, e) 100 µm; (b, d) 50 µm.
Difference in the color of background is due to use
of different filters.
Solar and seborrheic keratoses showed a S-IR pattern similar to
normal epidermis, survivin expression being confined to the basal
layer. S-IR was also observed in all epidermal layers in three of
four cases of Bowen’s diseases (Fig 2e). Six of seven cases of
SCC were S-IR positive, staining intensity being stronger in the
infiltrative component (Fig 2d). On the contrary, no S-IR was
observed in all cases of BCC but one, in which a very weak
positivity was appreciated. Interestingly, in BCC no S-IR was
observed in the epidermis just above the tumor, whereas it was
normally present in the basal layer of the normal epidermis adjacent
to the lesions.
S-IR in lymphoproliferative diseases (B and T cell lymphomas
and pseudolymphomas) was either weak or negative, in accordance
with previous observation in low-grade lymphomas, where survivin
was undetectable (Ambrosini et al, 1997). Merkel cell carcinoma
displayed medium-to-focally strong cytoplasmic S-IR.
Colonic adenocarcinoma, used as a positive control, showed
strong S-IR in the glandular component. No S-IR was detected
in negative controls treated either by preabsorbed antiserum or by
omission of the supernatant. No substantial difference in staining
intensity was appreciated in specimens treated with the Endogenous
Biotin Blocking Kit.
DISCUSSION
Using a combination of immunohistochemical and immunoblotting
techniques, we have shown the expression of the novel anti-
apoptosis protein survivin in normal human skin. Survivin immuno-
staining was confined solely to the proliferative basal layer of the
epidermis, whereas no staining was detected in the upper layers.
This pattern of expression was confirmed by immunoblot assay
performed on keratinocytes cultured in a low-calcium medium
which selects mostly basal cells. In human epidermis, apoptosis is
operational in the suprabasal layers, whereas basal keratinocytes
seem to maintain anti-apoptotic defenses (Haake and Polakowska,
1995). Indeed, endonuclease-induced DNA fragmentation is
observed in suprabasal, but not in basal keratinocytes (McCall and
Cohen, 1991). In addition, bcl-2 protein is expressed exclusively
in the germinative basal cell compartment (Hockenbery et al, 1991;
Rodriguez-Villanueva et al, 1995). Furthermore, it has been shown
recently that in basal keratinocytes an autocrine survival system
exists sustained by nerve growth factor that protects these cells
from apoptosis by inhibiting caspase activation, in a bcl-2-dependent
pathway (Pincelli et al, 1997; personal communication). Survivin
is abundantly expressed in proliferating cells (Li et al, 1998). In
addition, blocking survivin function results in increased caspase-3
activity, a mechanism involved in cell death (Li et al, 1998). Survivin
might thus participate in the anti-apoptotic mechanisms in the
proliferative basal cell compartment of human epidermis, possibly
acting as a direct caspase inhibitor, similarly to other IAP proteins
(Deveraux et al, 1997).
Interestingly, human skin seems to be the only normal adult
tissue expressing survivin (Ambrosini et al, 1997, 1998). Human
epidermis is characterized by a constant turnover of cells based on
the presence in the basal layer of a population of stem cells that
retains a high capacity of self-renewal throughout life. One could
speculate that survivin, similarly to bcl-2 (Hockenberry et al,
1991) protects the viability of regenerating stem keratinocytes, in
agreement with what has been proposed in fetal tissues (Adida et al,
1998). In this regard, we have recently demonstrated that putative
stem keratinocytes express high levels of bcl-2 and are protected
from apoptosis (manuscript in preparation).
Whereas survivin was highly expressed in SCC, in agreement
with the strong expression of this protein in other carcinomas
(Ambrosini et al, 1997), no immunostaining was detected in BCC.
This is at variance with the expression of bcl-2 that is abundant in
BCC and virtually lacking in SCC (Rodriguez-Villanueva et al,
1995; Wikonkal et al, 1997). Although the significance of this
finding requires further studies, it could point to different pathways
of survivin and bcl-2 as apoptosis inhibitors. In this regard, it has
been shown recently that X-linked IAP inhibit apoptosis in a
bcl-2-independent manner (Deveraux et al, 1997). Whereas the
relationship between bcl-2 and p53 in the pathomechanisms of
apoptosis is well defined (Pan et al, 1997) and p53 plays a major
part in the pathogenesis of SCC (Ziegler et al, 1994; Jonason et al,
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1996), nothing is known on the interplay between p53 and IAP
proteins. In SCC, survivin might counteract p53 activity, thus
inhibiting the apoptotic process and enhancing tumor development.
In summary, we have shown the expression of the novel anti-
apoptosis protein survivin in normal and pathologic skin. These
results suggest a possible involvement of survivin and its inhibitory
mechanisms in epidermal homeostasis. In addition, these studies
point to a putative role of survivin in the development of melanoma
and of certain nonmelanoma skin cancers.
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